Abstract
AbstractCardiovascular disease (CVD) is the most common cause of death in the United States and the industrialized world. The principal components of CVD are coronary heart disease (CHD), stroke, heart failure, and congenital heart disorders. Atherosclerosis, the chronic inflammatory arterial wall disease associated with the deposition of cholesterol into arterial plaques and hardening of the arteries, is a major contributor to CHD and is the principal cause of heart attacks and stroke. The risk factor most closely associated with a higher incidence of CHD is serum cholesterol levels. This report summarizes efforts in the pharmaceutical industry to manage cholesterol levels to reduce risk for CHD due to atherosclerosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
